Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610510 | 0.88 | OPRD1 (0.51) | OPRD1XIAPACE | |
| SCHEMBL3610424 | 0.81 | XIAP (0.47) | XIAPACELMNAHTTSMN1; SMN2 | |
| SCHEMBL3612848 | 0.78 | XIAP (0.47) | XIAPLMNAHTTSMN1; SMN2NPSR1 | |
| SCHEMBL3607627 | 0.76 | ACE (0.47) | XIAPACELMNAHTTSMN1; SMN2 | |
| SCHEMBL3607354 | 0.76 | ACE (0.46) | XIAPACELMNAHTTSMN1; SMN2 | |
| SCHEMBL3612560 | 0.74 | MAPT (0.41) | XIAPLMNAHTTSMN1; SMN2NPSR1 | |
| SCHEMBL3605762 | 0.74 | XIAP (0.42) | XIAPACELMNAHTTSMN1; SMN2 | |
| SCHEMBL3597908 | 0.73 | TP53 (0.46) | LMNAHTTSMN1; SMN2NPSR1 | |
| SCHEMBL3598720 | 0.73 | XIAP (0.45) | XIAPACE | |
| SCHEMBL3612495 | 0.70 | XIAP (0.50) | XIAPACEHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | OPRD1 2002/4885HDAC8 375/4885XIAP 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.